| Time | Session |
|---|---|
|
14:00
15:40
|
(pre-selected participants only; UPDATE: this session is fully booked)
Room F1+2+3
|
|
15:40
16:10
|
Refreshment Break.
|
|
16:10
18:25
|
(pre-selected participants only; UPDATE: this session is fully booked)
Room F1+2+3
|
|
18:30
20:00
|
Early Career Networking Reception
Main Foyer
Room F1+2+3
|
| Time | Session | |||||
|---|---|---|---|---|---|---|
|
08:30
10:00
|
(pre-selected participants only; UPDATE: this session is fully booked)
Room F1+2+3
|
|||||
|
09:00
14:00
|
Women in Leadership
(Separate pre-registration required)
Off-site Venue
|
|||||
|
10:00
12:00
|
Room F6+7+8
|
|||||
|
10:30
12:00
|
This session focuses on career progression, offering participants the opportunity to engage directly with the four Award Winners in an informal, highly interactive format. Each expert will begin with a 7 minute personal introduction, sharing their career path, key decisions, and lessons learned. A moderator may pose follow-up questions to deepen the discussion and draw out practical insights. The floor is then opened to the audience for an open Q&A, encouraging participants to ask questions in an “Ask Me Anything”–style exchange. Designed as a fully interactive session, this format features no slides and no screen, prioritizing conversation, accessibility, and direct engagement between Award Winners and participants.
Career Development Area
|
(pre-selected participants only; UPDATE: this session is fully booked)
Room F1+2+3
|
||||
|
12:00
14:00
|
Lunch Break / Exhibition (Poster and Exhibition Hall)
Poster and Exhibition Hall
Room P1+2+3
|
|||||
|
12:00
20:00
|
Exhibition
Poster and Exhibition Hall
|
|||||
|
12:15
13:00
|
This symposium addresses the critical shift toward multi-resolution, multi-modal approaches that enable the precise deconstruction of the tumor ecosystem to achieve a system-level understanding of cancer progression. The session will begin with an overview of emerging innovations expanding the resolution and scope of cancer research, followed by expert‑led research demonstrating the utility of spatial transcriptomics for tumor microenvironment analysis and high‑plex functional proteomics for uncovering protein‑level drivers of cancer biology. Building on these applications and using Illumina Connected Multiomics (ICM) as a framework, an R&D‑led technical deep dive will examine analytical considerations for single‑omic and integrated multiomic analysis across single‑cell, spatial, transcriptomic, proteomic, genomic, and epigenomic data. Through practical examples, this session will demonstrate how AI guided workflows, structured data exploration, and intuitive visualisation make advanced multiomic analysis accessible, enabling researchers to confidently apply multiomic approaches in their own studies. Join us to explore how these multidimensional results, powered by high‑fidelity sequencing and accessible data analytics are providing the clarity needed to decipher the functional drivers of cancer and advance the next wave of precision oncology.
Room F1+2+3
|
Biology is complex, and the mechanisms that drive biological systems are challenging to decipher. Examining any single layer of biology can provide a valuable perspective, but it reveals only part of the picture. Bruker Spatial Biology delivers best-in-class solutions designed to work together as a cohesive ecosystem. By providing high fidelity resolution and information depth across layers of biological complexity, Bruker Spatial Biology enables insights that cannot be achieved by single layer approaches, accelerating discovery through translational cancer research. Prof. Pagani will exemplify how his laboratory is using CosMx Same-Cell Multiomics to determine metastatic cell states in colorectal cancer.
Room F9+10
|
||||
|
12:30
13:45
|
(open to EACR Early Career & Student Members, pre-registration required)
Career Development Area
|
|||||
|
13:15
14:00
|
This symposium addresses the critical shift toward multi-resolution, multi-modal approaches that enable the precise deconstruction of the tumor ecosystem to achieve a system-level understanding of cancer progression. The session will begin with an overview of emerging innovations expanding the resolution and scope of cancer research, followed by expert‑led research demonstrating the utility of spatial transcriptomics for tumor microenvironment analysis and high‑plex functional proteomics for uncovering protein‑level drivers of cancer biology. Building on these applications and using Illumina Connected Multiomics (ICM) as a framework, an R&D‑led technical deep dive will examine analytical considerations for single‑omic and integrated multiomic analysis across single‑cell, spatial, transcriptomic, proteomic, genomic, and epigenomic data. Through practical examples, this session will demonstrate how AI guided workflows, structured data exploration, and intuitive visualisation make advanced multiomic analysis accessible, enabling researchers to confidently apply multiomic approaches in their own studies. Join us to explore how these multidimensional results, powered by high‑fidelity sequencing and accessible data analytics are providing the clarity needed to decipher the functional drivers of cancer and advance the next wave of precision oncology.
Room F1+2+3
|
γδ T cells are increasingly recognized for their role in anti-tumor immunity and Vδ1 T cells have been reported as the predominant γδ subset infiltrating the microenvironment of several cancers. However, their contribution in this setting remains unclear and flow cytometry alone has provided limited insights into their functionality. In this symposium, Prof. Domenico Mavilio (IRCCS Humanitas Research Hospital, Milan, Italy) will present how transcriptome and repertoire profiling at bulk and single cell resolution can clarify γδ T-cell states and provide clues on tumor escape mechanisms. By linking transcriptional state, repertoire, and therapeutic response, this work underscores the potent antitumor role of Vδ1 T cells in endometrial cancer and highlights their potential as therapeutic targets to enhance anti–PD-1 checkpoint inhibitor strategies in the future.
Room F9+10
|
||||
|
14:00
15:15
|
Room F1+2+3
|
Room F6+7+8
|
Room P1+2+3
Room P1+2+3
|
|||
|
15:15
15:45
|
Meet and Greet EACR Ambassador and Solo Travellers (at the Networking Lounge)
Networking Lounge
|
Coffee Break / Exhibition (Poster and Exhibition Hall)
Poster and Exhibition Hall
Room P1+2+3
|
||||
|
15:45
18:20
|
Room P1+2+3
|
|||||
|
18:20
18:35
|
EACR General Assembly and Awards Ceremony (EACR Members only)
P1+2+3
Room P1+2+3
|
Welcome Reception (Exhibition Area)
Poster and Exhibition Hall
Room P1+2+3
|
||||
|
18:45
19:00
|
CancerTools.org Industry Spotlight Session: Accelerating cancer research with CancerTools: Unlocking discovery with advanced models
Malathi Raman Srivastava is a Senior Product Marketing Manager at CancerTools managing the breast, lung and skin cancer product portfolios including patient-derived xenograft (PDX) models. She previously worked at Bit Bio Ltd as a Product Development Manager and at Takara Bio Europe as a Senior Product Manager. She holds a PhD from Imperial College London and has done post-doctoral research at the Leeds Institute of Molecular Medicine in Leeds, U.K.
Spotlight Theatre
|
|||||
|
19:15
19:30
|
Element Biosciences Industry Spotlight Session: Revealing a Deeper View of Cancer with 5D Biology
Spotlight Theatre
|
|||||
| Time | Session | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
08:30
09:15
|
This interactive session focuses on grant funding, offering participants direct access to funders and grantmakers. Each expert will give a 5-minute introduction, outlining their role, funding priorities, and perspectives on the grant-making process. A moderator will pose follow-up questions to deepen the discussion and highlight practical insights. The session then opens to the audience for an open “Ask Me Anything” Q&A, encouraging candid questions and active participation. Designed as a fully interactive format, the session includes no slides or screens, prioritizing conversation and direct engagement.
Career Development Area
|
Join Atlas Antibodies for an exploration into the evolution of spatial proteomics, rooted in the 20-year legacy of the Human Protein Atlas (HPA). This symposium demonstrates how the rigorously validated primary antibodies that built the HPA are now driving advanced functional discovery in cancer research. The session will cover two key technical workflows: Atlasplex, a streamlined solution for targeted 3-5 marker multiplexing, and Molboolean, an innovative technology using rolling circle amplification to detect protein-protein interactions in situ. Attendees will learn how to bridge the gap between static tissue maps and dynamic functional insights, utilizing high-certainty reagents to characterize cellular "neighborhoods" and molecular interactions. Whether you are looking to optimize your multiplexing efficiency or investigate protein-protein complexes, this session provides a practical roadmap for turning routine IHC into high-dimensional data.
Room F1+2+3
|
Liquid biopsy is widely used for cancer detection and monitoring, but DNA-based approaches remain limited in early-stage sensitivity and dynamic biological insight. We present a nanopore-enabled RNA liquid biopsy platform that profiles full-length cell-free RNA (cfRNA) from blood which has the potential to enable early detection, longitudinal monitoring, and precision oncology applications. Long-read nanopore sequencing of samples from healthy, precancerous, and early-stage cancer research subjects reveals over 270,000 previously unannotated cfRNA transcripts, enabling construction of an expanded transcriptome reference. Machine learning enables accurate research classification of precancer and cancer while capturing pathway-level signals, including metabolic, mitochondrial, and immune checkpoint activity. This approach provides real-time, systemic readouts of tumor activity from blood, with the future potential to enable patient stratification, residual disease assessment, and monitoring of therapeutic response and emerging resistance. The platform is designed for integration with clinical workflows and DNA-based assays, supporting future, scalable deployment across diagnostic and clinical trial settings. This framework establishes a path to integrate RNA-based profiling with DNA-based approaches, potentially enhancing the impact and utility of multiomic liquid biopsies across detection, monitoring, and treatment.
Room F6+7+8
|
|||||||||
|
09:20
10:55
|
Room F1+2+3
|
Room F6+7+8
|
Room P1+2+3
Room P1+2+3
|
|||||||||
|
10:30
20:00
|
||||||||||||
|
10:30
19:00
|
Exhibition
Poster and Exhibition Hall
Poster and Exhibition Hall
|
|||||||||||
|
10:55
11:35
|
Coffee Break / Exhibition / Industry Spotlight (Poster and Exhibition Hall)
Exhibition and Poster Hall
Room P1+2+3
|
|||||||||||
|
11:10
11:25
|
Spotlight Theatre
|
|||||||||||
|
11:35
13:10
|
Room F1+2+3
|
Room F6+7+8
|
Room F9+10
|
Room P1+2+3
Room P1+2+3
|
||||||||
|
13:15
15:15
|
Lunch Break / Exhibition / Poster Viewing
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
|
13:30
14:15
|
Droplet Digital PCR (ddPCR) provides ultrasensitive, quantitative detection of low-frequency tumour variants in plasma and tissue, reliably identifying mutations below 1% allele frequency. In metastatic breast cancer, ddPCR detects ESR1 mutations (reported in >60% of patients) and enables circulating tumour DNA monitoring; its clinical value is supported by a European early access program and helps guide personalised therapy, including selective estrogen receptor degraders. In metastatic NSCLC, where response biomarkers for chemo-immunotherapy are limited, the B-IO study tracks tumour-informed, patient-specific mutations by longitudinal multicolor ddPCR in 73 stage IV patients after TKI progression to predict treatment response.
IreneHernandez Perez
Industry Speaker
Laboratorio de Patología Molecular, Fundación Jiménez Díaz Health Research InstituteSpain
PimRozendal
Industry Speaker
Department of Pathology, University Medical Center GroningenNetherlands
Room F1+2+3
|
This session, sponsored by biomodal, will introduce the duet cfDNA solutions as complete integrated genetic and epigenetic workflows and software. The duet cfDNA solutions unlock the broadest spectrum of biomarkers, with market leading accuracy, from a single low input cfDNA sample, enabling ultra-low LoD for the detection of ctDNA. Talks will demonstrate how, in a liquid biopsy setting, 6-base data detects cancers earlier than other methylation sequencing approaches across multiple cohorts. Additional data will show how 6-base data enables a better understanding biological mechanisms of prostate cancer treatment response than existing liquid biopsy approaches.
Room F6+7+8
|
Dr. Wiesner will highlight how Advanced Cell Diagnostics and Lunaphore, Bio-Techne brands, are transforming the future of oncology research and precision medicine with spatial biology tools. Dr. Karen, from the Weizmann Institute of Science, will talk about how modern lung cancer treatment depends on multiple biomarkers, but current diagnostic workflows exhaust small biopsies and slow down life-saving therapy decisions. Her team developed a multiplexed imaging approach that reads dozens of markers from one tissue section, enabling comprehensive diagnosis while conserving tissue and shortening turnaround time. The last talk will present the application of RNAscopeTM, BaseScopeTM, and COMETTM technologies for highly sensitive spatial detection of RNA molecules, point mutations, and proteins at single-cell resolution.
Room F9+10
|
|||||||||
|
13:45
15:00
|
(open to EACR Early Career & Student Members, pre-registration required)
Career Development Area
|
|||||||||||
|
14:30
15:15
|
Discover how 3D chromatin organization acts as a master regulator of leukemia biology, learn cutting-edge approaches to profile spatial genome architecture in cancer, and understand how linking chromatin structure to gene expression networks can identify new precision medicine strategies for improving patient outcomes. • Learn how 3D chromatin conformation capture can distinguish leukemia subtypes and pinpoint their cells of origin by mapping lineage-defining regulatory hubs. • Explore how 3D genome profiling uncovers intra‑tumor heterogeneity in T‑ALL, providing new biomarkers to anticipate and monitor therapy response. • See how chromatin interaction matrices expose structural variants and enhancer hijacking events that drive oncogene activation and leukemic transformation.
Room F1+2+3
|
Over three decades, 3DHISTECH has advanced digital pathology through comprehensive 2D imaging solutions spanning the entire diagnostic workflow. Yet tissue is inherently three dimensional. The Pannoramic X micro CT introduces a breakthrough in 3D digital pathology by enabling ultra-high resolution imaging of intact FFPE blocks, macroblocks, and large specimens without sectioning or staining. Using soft X ray virtual slicing and staining, it preserves tissue integrity while revealing unprecedented morphological and biomarker detail. Integrated with advanced visualization and AI driven analysis, the system enhances tumor assessment, cancer staging, and research applications. The future of pathology is volumetric—unlocking deeper insight through true 3D tissue exploration.
Room F6+7+8
|
Understanding tumor biology requires both spatial context and deep molecular insight. In this session Heidi Haikala (University of Helsinki) will share her latest research on tumor–immune interactions in lung cancer, highlighting how advanced transcriptomic approaches can uncover complex biology in the tumor microenvironment. René-Filip Jackstadt (DKFZ) will present new findings on colorectal cancer progression in space and time, including first data generated using Atera In Situ. Together, these talks illustrate how cutting-edge single cell & spatial technologies are expanding our ability to study cancer in its native context.
HeidiM.Haikala
Industry Speaker
Institute of Molecular Medicine Finland (FIMM), University of HelsinkiFinland
Room F9+10
|
|||||||||
|
15:20
16:55
|
Room F1+2+3
|
Room F6+7+8
|
Room F9+10
|
Room P1+2+3
Room P1+2+3
|
||||||||
|
16:55
17:30
|
Coffee Break / Exhibition / Industry Spotlight (Poster and Exhibition Hall)
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
|
17:10
17:25
|
Cutaneous squamous cell carcinoma (SCC) is a primary driver of mortality in patients with recessive dystrophic epidermolysis bullosa (RDEB), necessitating the discovery of safe, effective systemic or topical therapies. Using transcriptome-guided drug repurposing, we identified statins as a potential therapeutic intervention for RDEB-associated SCC. In vitro, lovastatin exhibited significant cytostatic effects and induced caspase-dependent apoptosis. This effect was rescued by mevalonate and geranylgeraniol, confirming on-target inhibition of the mevalonate pathway. While topical application of lovastatin in an in vivo xenograft model resulted in significant reduction in tumor growth, we could observe that its efficacy was limited by rapid clearance from the tumor and the induction of compensatory feedback mechanisms. Our findings suggest that while the established safety profile of statins makes them highly attractive candidates for repurposing, clinical success will depend on overcoming two critical barriers: establishing dosing regimens that maintain therapeutic levels below the threshold of local toxicity and developing strategies to circumvent secondary feedback loops.
Spotlight Theatre
|
|||||||||||
|
17:30
18:15
|
Room P1+2+3
|
|||||||||||
|
18:15
18:40
|
Spotlight Theatre
Room P1+2+3
|
|||||||||||
|
18:40
20:00
|
||||||||||||
| Time | Session | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
08:30
09:15
|
This interactive session explores collaboration between industry and academia, offering practical perspectives from industry experts. Each expert will deliver a 5-minute introduction, sharing their experience, role, and insights into working across sectors. A moderator will guide the discussion with follow-up questions to deepen the conversation and surface actionable takeaways. The session then opens to the audience for an open “Ask Me Anything” Q&A, encouraging questions and active participation. Designed as a fully interactive format, the session features no slides or screens, prioritizing dialogue and direct engagement.
Career Development Area
|
TP53 mutations are common in AML, often as “multi-hit” types linked to complex karyotypes. Using single-cell DNA sequencing and phenotypic analysis, we examined the zygosity and clonal architecture of TP53m AML. Among eight patients, “multi-hit” TP53 anomalies appeared in blast cells but not in mature lymphoid populations. Minor TP53m heterozygous clones persisted in mature cells and at remission, with dominant “multi-hit” clones resurfacing at relapse. The combined scDNAseq and CITEseq approach highlights distinct mutation patterns, aiding therapy guidance by distinguishing pathological multi-hit mutations from clonal haematopoiesis at remission.
Room F6+7+8
|
||||||||||
|
09:20
10:55
|
Room F1+2+3
|
Room F6+7+8
|
Room P1+2+3
Room P1+2+3
|
|||||||||
|
10:30
20:00
|
||||||||||||
|
10:30
19:00
|
Exhibition
Poster and Exhibition Hall
|
|||||||||||
|
10:55
11:35
|
Coffee Break / Exhibition / Industry Spotlight (Poster and Exhibition Hall)
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
|
11:10
11:25
|
We will present tools, platforms, and customer case studies highlighting the utility of functional screening and immune profiling for target discovery and validation.
Spotlight Theatre
|
|||||||||||
|
11:35
13:10
|
Room F1+2+3
|
Room F6+7+8
|
Room F9+10
|
Room P1+2+3
Room P1+2+3
|
||||||||
|
13:15
15:15
|
Lunch Break / Exhibition / Poster Viewing
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
|
13:30
14:15
|
Understanding cancer biology through a single molecular lens often leaves critical mechanisms unresolved. Increasingly, researchers are combining complementary molecular layers to build a more comprehensive view of disease—connecting genetic, epigenetic, proteomic, and spatial signals to better understand tumor development, heterogeneity, and progression. This symposium brings together scientists applying integrated multiomic approaches to address complex biological questions in cancer research. By featuring perspectives from researchers at different stages of their scientific careers, the session highlights how connecting diverse molecular signals into a unified analytical view is driving biological discovery and translational investigation. Together, these perspectives illustrate how examining cancer biology from multiple, complementary molecular angles supports a more comprehensive understanding of cancer biology.
Room F1+2+3
|
F.Hoffmann - La Roche Industry Symposium: Optimizing T-Cell Redirection: The Added Value of Costimulatory Bispecifics
Roche is pioneering costimulatory bispecifics targeting 4-1BB and CD28 to maximize the efficacy of T-cell bispecifics (TCBs) and enable chemotherapy-free regimens in early-line therapy. This session explores phase 1 biomarker data from FAP-4-1BBL, CD19-4-1BBL, and CD19-CD28 trials across solid and hematologic indications. We will present evidence of a costimulatory "Signal 2" mode of action and its contribution to clinical efficacy. Furthermore, we share findings on the distinct “personalities” of each costimulator, providing a roadmap for this emerging therapeutic class.
Room F6+7+8
|
FFPE is the most abundant clinical sample type used in cancer research. However, extracting high-quality genomic, transcriptomic, and proteomic data from FFPE remains a major challenge. This symposium explores robust and reliable sample preparation workflows that transform FFPE from a difficult specimen into a powerful resource for multi-Omics analysis. Experts will highlight AFA enabled workflows that maximize analyte recovery, preserve molecular integrity, and deliver confident results for DNA, RNA, and proteins. Discover how integrated, automation ready workflows can provide deeper insights from FFPE, thereby accelerating biomarker discovery, translational research, and precision oncology.
Room F9+10
|
|||||||||
|
13:45
15:00
|
(open to EACR Early Career & Student Members, pre-registration required)
Career Development Area
|
|||||||||||
|
14:30
15:15
|
Spatial biology enables detailed analysis of molecular processes within native tissue architecture. Using MACSima® Imaging Cycling Staining (MICS), hundreds of proteins and dozens of RNA markers can be detected on the same section, generating high dimensional datasets that enhance cellular characterization and improve therapeutic target solutions. After an introduction into Miltenyi Biotec's innovative spatial biology and imaging solutions, we will demonstrate how B cells play a pivotal role in shaping the TME and tertiary lymphoid structures (TLS). The functions of specific B cell subsets in cancer pathogenesis remain unclear. Using a tissue-centric single-cell RNA-sequencing pipeline, flow cytometry, and high-plex spatial biology MACSima platform, we identify CD27⁻IgD⁻CD21⁺CD11c⁻ double negative 1 (DN1) B cells as a regulatory population enriched in RCC tumours and associated with worse prognosis. These cells localize within immature tertiary lymphoid structures near IL-10⁺ and TGFβ⁺ CD8⁺ T cells. TLR signalling drives their differentiation, and DN1 B cells suppress CD8⁺ T cell cytotoxicity partially via IL-10 and TGFβ. Our findings reveal a novel immune evasion mechanism with potential diagnostic and therapeutic relevance.
Room F1+2+3
|
Biology is complex, and the mechanisms that drive biological systems are challenging to decipher. Examining any single layer of biology can provide a valuable perspective, but it reveals only part of the picture. Bruker Spatial Biology delivers best-in-class solutions designed to work together as a cohesive ecosystem. By providing high fidelity resolution and information depth across layers of biological complexity, Bruker Spatial Biology enables insights that cannot be achieved by single layer approaches, accelerating discovery through translational cancer research. Prof. Pagani will exemplify how his laboratory is using CosMx Same-Cell Multiomics to determine metastatic cell states in colorectal cancer.
Room F6+7+8
|
Proteomics is gaining increasing attention in cancer research by providing functional insights beyond genomics and driving novel biomarker discovery. This symposium highlights how high-throughput proteomics enables a deeper understanding of tumor biology, early detection, and treatment response.
Room F9+10
|
|||||||||
|
15:20
16:55
|
Room F1+2+3
|
Room F6+7+8
|
Room F9+10
|
Room P1+2+3
Room P1+2+3
|
||||||||
|
16:55
17:30
|
Coffee Break / Exhibition / Industry Spotlight (Poster and Exhibition Hall)
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
|
17:10
17:25
|
Discover how ATCC’s advanced human models are helping to move cancer research beyond traditional cell lines. From engineered cells to organoids, these biologically relevant systems provide more predictive and translational insights, helping researchers better capture the complexity of human tumours and accelerate progress from discovery to therapeutic development.
Spotlight Theatre
|
|||||||||||
|
17:30
18:15
|
Room P1+2+3
|
|||||||||||
|
18:15
18:40
|
Spotlight Theatre
Room P1+2+3
|
|||||||||||
|
18:40
20:00
|
||||||||||||
| Time | Session |
|---|---|
|
09:00
09:45
|
Room P1+2+3
|
|
09:45
11:00
|
Room P1+2+3
|
|
11:00
11:20
|
Coffee Break
Main Foyer
Room P1+2+3
|
|
11:20
12:05
|
Room P1+2+3
|
|
12:05
13:00
|
Room P1+2+3
|